Incyte’s blockbuster JAK inhibitor Jakafi has been driving the company’s sales for years now, with this quarter being no different. But, as an end-of -decade patent cliff approaches, the company is turning to new potential growth drivers to make up for the looming loss. 

Incyte has announced positive topline data from the Phase III inMIND trial evaluating its CD19-targeting monoclonal antibody Monjuvi (tafasitamab) in patients with relapsed or refractory (r/r) follicular lymphoma.

OptumRx, the pharmacy benefit unit of UnitedHealth Group, recently released a report detailing three drugs that it expects to have a significant impact on the pharmaceutical industry in 2020.

The FDA has approved 30 new drugs this year, slightly above the average annual number, and five approvals have been delayed due to COVID-19, OptumRx said in the report.

The FDA approved Monjuvi for second-line diffuse large B-cell lymphoma. Though the drug has the same antigen target as approved CAR-T cell therapies, it is designed for patients unable to tolerate such intensive treatments.